Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

6.57USD
26 May 2017
Change (% chg)

$-0.20 (-2.95%)
Prev Close
$6.77
Open
$6.75
Day's High
$6.78
Day's Low
$6.54
Volume
177,921
Avg. Vol
392,223
52-wk High
$11.71
52-wk Low
$4.01

Select another date:

Thu, May 4 2017

BRIEF-Progenics Pharmaceuticals reports Q1 loss per share $0.23

* Progenics pharmaceuticals announces first quarter 2017 financial results and business update

BRIEF-Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®

* Progenics Pharmaceuticals announces positive topline results from registrational phase 2b trial of azedra®

BRIEF-Progenics Pharmaceuticals posts Q4 loss per share $0.10

* Progenics Pharmaceuticals announces fourth quarter and full-year 2016 financial results and business update

BRIEF-Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment

* Progenics Pharmaceuticals announces initiation of a phase 1 clinical trial of its PSMA-targeted therapeutic candidate 1095 for the treatment of metastatic prostate cancer Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald

* Entered controlled equity offering sales agreement with Cantor Fitzgerald, pursuant to which Co may offer, sell up to $75 million stock Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharmaceuticals files for mixed shelf of up to $250 mln - SEC filing

* Progenics Pharmaceuticals Inc - files for mixed shelf of up to $250 million - SEC filing Source text: (http://bit.ly/2jcUEzy) Further company coverage:

Select another date:

More From Around the Web